Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 22 2022 - 8:05AM
Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset
clinical-stage biopharmaceutical company, focused on identifying,
developing and commercializing treatments in high unmet need areas
involving rare diseases and multi-drug resistant (MDR) bacterial
infections, today announced that Ankit Mahadevia, M.D., President
and Chief Executive Officer of Spero Therapeutics, will
participate in a fireside chat and be available for one-on-one
meetings at the 5th Annual Evercore ISI HealthCONx Conference,
which is taking place virtually, November 29, 2022 through December
1, 2022. Details for the fireside chat are as follows:
5th
Annual Evercore ISI HealthCONx Conference
Fireside Chat Date & Time:
Tuesday, November 29, 2022, at 8:00 AM ETWebcast
Link:
https://wsw.com/webcast/evercore29/spro/2408280
A webcast of the fireside chat may also be
accessed through Spero Therapeutics’ website
(www.sperotherapeutics.com) on the “Events and Presentations” page
under the “Connect” tab. A replay of the fireside chat will be
available on the website following the conclusion of the event.
About Spero TherapeuticsSpero
Therapeutics, headquartered in Cambridge, Massachusetts, is a
multi-asset, clinical-stage biopharmaceutical company focused on
identifying, developing, and commercializing novel treatments for
bacterial infections, including multi-drug resistant bacterial
infections and rare diseases.
- Spero Therapeutics is
developing SPR720 as a novel oral therapy candidate for the
treatment of a rare, orphan pulmonary disease caused by
non-tuberculous mycobacterial infections.
- Tebipenem HBr is an investigational
drug in the United States being developed for the treatment of
cUTI, including pyelonephritis, caused by certain bacteria, in
adult patients who have limited treatment options; tebipenem HBr is
not FDA-approved.
- Spero Therapeutics also has an
IV-administered next generation polymyxin product candidate,
SPR206, developed from its potentiator platform, which is in
development to treat multi-drug resistant Gram-negative infections
in the hospital setting.
For more information,
visit https://sperotherapeutics.com.
Forward Looking StatementsThis press release
may contain forward-looking statements. These statements include,
but are not limited to, statements about the regulatory path
forward for tebipenem HBr and potential FDA approval, the potential
commercialization of tebipenem HBr and its future value, the
potential receipt of milestone payments and royalties on future
sales under the GSK license agreement, the design, initiation,
timing, progress and results of Spero's preclinical studies and
clinical trials and its research and development programs, and
Spero’s cash runway. In some cases, forward-looking statements can
be identified by terms such as “may,” “will,” “should,” “expect,”
“plan,” “aim,” “anticipate,” “could,” “intent,” “target,”
“project,” “contemplate,” “believe,” “estimate,” “predict,”
“potential” or “continue” or the negative of these terms or other
similar expressions. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors, including whether tebipenem HBr will
advance through the clinical trial process on a timely basis, or at
all, taking into account the effects of possible regulatory delays,
slower than anticipated patient enrollment, manufacturing
challenges, clinical trial design and clinical outcomes; whether
the results of such trials will warrant submission for approval
from the FDA or equivalent foreign regulatory agencies;
whether the FDA will ultimately approve tebipenem HBr and, if so,
the timing of any such approval; whether the FDA will require any
additional clinical data or place labeling restrictions on the use
of tebipenem HBr that would delay approval and/or reduce the
commercial prospects of tebipenem HBr; whether a successful
commercial launch can be achieved and market acceptance of
tebipenem HBr can be established; the lengthy, expensive, and
uncertain process of clinical drug development for SPR720 and
SPR206; whether results obtained in preclinical studies and
clinical trials will be indicative of results obtained in future
clinical trials; Spero's reliance on third parties to manufacture,
develop, and commercialize its product candidates, if approved; the
ability to commercialize Spero's product candidates, if approved;
Spero's ability to retain key personnel; whether Spero’s cash
resources will be sufficient to fund its continuing operations for
the periods and/or trials anticipated; and other factors discussed
in the “Risk Factors” set forth in filings that Spero periodically
makes with the U.S. Securities and Exchange Commission. The
forward-looking statements included in this press release represent
Spero’s views as of the date of this press release. Spero
anticipates that subsequent events and developments will cause its
views to change. However, while Spero may elect to update these
forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Spero’s views as of any date subsequent to the date of
this press release.
Investor Relations Contact: Ted
JenkinsVice President, Head of Investor
RelationsTjenkins@sperotherapeutics.com (617) 798-4039
Media Inquiries: Lora Grassilli, Health Media
Relations
Zeno
Grouplora.grassilli@zenogroup.com
646-932-3735
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Sep 2023 to Sep 2024